Bought the seat, waiting for the ride: management describes a position already secured inside someone else's decision, w
The model's full reasoning — Q3 2023 call → NOThe question asks whether management conveys that the company's near-term growth no longer depends on persuading anyone because decisions governing it have already been made by others, and the resulting activity has only just begun to reach the company. Let me analyze the transcript for the three conditions: (1) THE DECISION IS BEHIND THEM, NOT AHEAD OF THEM. Management describes the company's forward business as resting on choices outside parties have ALREADY made in its favor, so what remains is delivery rather than winning. Looking at the transcript: The company has received regulatory approvals in Brazil and Canada. They have distribution agreements in Portugal, India, China, Japan. The ICE3 trial is ongoing. The FDA denied the De Novo request, and they filed an appeal - this is still pending, so the FDA decision is NOT behind them for the breast cancer indication in the U.S. However, for other markets, approvals have been granted. But the key question is about near-term growth. The company's growth seems to rest on: - Distribution agreements already signed (Portugal, Brazil, China, Japan) - Regulatory approvals already obtained (Brazil, Canada) - The ICE3 trial completion However, the FDA appeal is still pending - that's a decision ahead of them, not behind them. The appeal response is expected by end of January 2024. (2) THE COMPANY IS BEHAVING LIKE SOMEONE PREPARING TO DELIVER. Management's account of what the organization is doing now is dominated by getting ready and getting it out the door. The transcript mentions: training KOLs, attending conferences, expanding distribution, hiring a VP of sales for North America, working with distributors. There's some of this - they mention "we are also experiencing a high-tended level of interest for our ProSense system" and they're working on commercial penetration. (3) THE COMPANY IS SMALL RELATIVE TO WHAT HAS BEEN COMMITTED, AND THE NUMBERS DON'T SHOW IT YET. Revenue is about $2 million for nine months, sales increased 11% to $1.7 million. The company has $13.2 million in cash. There's no strong indication that committed business is large relative to current size. The key issue: The FDA decision is still pending - the appeal is ahead of them. The company's main regulatory path for the U.S. breast cancer indication is still uncertain. The company is still pursuing approvals and winning business.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GOGO · Q1 2016 → YESThe question is whether management conveys that the company's near-term growth no longer depends on persuading anyone, because decisions have already been made by others, and activity has just begun t...YES The transcript shows management describing 2Ku awards exceeding 1000 aircraft as already decided by airlines (IAG, Air Canada, Delta, Shareco), with activity now centered on installation, STCs, and supply chain mobilization rather than further persuasion.
GIII · Q4 2024 → YESThe question is whether management conveys that the company's near-term growth no longer depends on persuading anyone, because decisions have already been made by others, and activity has just begun t...
FLL · Q3 2022 → YESThe question is about whether management conveys that the company's near-term growth no longer depends on persuading anyone, because decisions have already been made by others, and activity has just b...